Lonza starts up second phase of Nansha API facility
Swiss pharmaceutical firm Lonza is continuing its expansion in China with the start-up of the second phase of its large-scale API facility in Nansha.
Swiss pharmaceutical firm Lonza is continuing its expansion in China with the start-up of the second phase of its large-scale API facility in Nansha.
This facility combines state-of-the art facilities, development services and cGMP chemical manufacturing plants. It is fully integrated with facilities for administration, research and development, a kilo lab, and both small- and large-scale production. Seventy scientists provide r&d services in a 1,000m2 lab area.
"The build-out of our Nansha operations proceeds as planned and we are happy that the second phase went on-line in accordance with our timelines and budget," said Uwe Boehlke, coo, Lonza Custom Manufacturing, Exclusive Synthesis. "We are now able to offer our clients even greater flexibility as the newly added capacity operates with multiple train sizes."
The new large-scale facility in Nansha is a five-train, multipurpose API manufacturing complex. With the completion of phase 2, the first three trains are fully operational, totalling 126m3 of reactor volume. Off gases and wastewater are treated in accordance with Lonza's global safety, health and environmental standards.